Latest Breaking News On - Boditech med inc - Page 6 : vimarsana.com

Pancreatic Cancer Diagnostics Market is Likely to Upsurge at a CAGR of 7 5% by 2030, Size, Share, Trends, Demand, Growth, Opportunities and Competitors Analysis

/PRNewswire/ Data Bridge Market Research Published Latest Pancreatic Cancer Diagnostics Market Study by in-depth analysis of the current scenario, the.

United statesHong kongUnited kingdomSouth koreaSouth africaSumatera utaraSaudi arabiaKoninklijke philipsAgilent technologies incCompany landscapeRoute of administration oralAccubiotech co ltdSiemens healthcare privateHoldings america corporationBrowsea detailed summary of the researchMeridian life science inc

Data Bridge Market Research: Pancreatic Cancer Diagnostics Market is Likely to Upsurge at a CAGR of 7 5% by 2030, Size, Share, Trends, Demand, Growth, Opportunities and Competitors Analysis

HOUSTON, Jan. 25, 2023 /PRNewswire/ Data Bridge Market Research Published Latest Pancreatic Cancer Diagnostics Market Study by in-depth analysis of the current scenario, the Market size,

United statesHong kongUnited kingdomSouth koreaSouth africaSumatera utaraSaudi arabiaKostenloser wertpapierhandelKoninklijke philipsAgilent technologies incCompany landscapeRoute of administration oralAccubiotech co ltdSiemens healthcare privateHoldings america corporationBrowsea detailed summary of the research

EQS-News: SphingoTec GmbH: Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

Issuer: SphingoTec GmbH / Key word(s): Agreement/Contract Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid) 15.11.2022

Kangwon doSouth koreaRepublic of koreaKostenloser wertpapierhandelSphingotec gmbhEui yul choiSphingotec gmbRuxandra lenzBoditech med incClin chem labDistribution servicesYul choiBoditech medRev dis primersEarly biomarkerSeptic acute kidney injury

Boditech Med and SphingoTec Close Global Licensing Agreement for Kidney Function Biomarker Proenkephalin A 119-159 (penKid)

Boditech Med and SphingoTec Close Global Licensing Agreement for Kidney Function Biomarker Proenkephalin A 119-159 (penKid)
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

South koreaKangwon doRepublic of koreaSphingotec gmbh hennigsdorfSphingotec gmbhEui yul choiSphingotec gmbRuxandra lenzBoditech med incClin chem labBoditech medYul choiEarly biomarkerSeptic acute kidney injurySeptic shockChem lab

SphingoTec GmbH: Boditech Med and SphingoTec Close Global Licensing Agreement for Kidney Function Biomarker Proenkephalin A 119-159

Worldwide licensing agreement signed to develop and offer penKid as test on Boditech's fully automated immunoassay systems.The biomarker penKid adds diagnostic value and addresses current unmet needs in

Kangwon doSouth koreaRepublic of koreaKostenloser wertpapierhandelSphingotec gmbhSphingotec gmbhviewEui yul choiSphingotec gmbRuxandra lenzBoditech med incClin chem labBoditech medYul choiEarly biomarkerSeptic acute kidney injurySeptic shock